



20 March 2018

ASX ANNOUNCEMENT

Global demand for Medical Developments Shares.

Medical Developments International Ltd (ASX: MVP) advises that its Chairman, Mr. David Williams sold 5 million MVP shares off-market yesterday, at \$7.50 per share.

MVP Chairman Mr. David Williams said: "MVP recently completed a three-week road show where 48 financial institutions from Europe, Asia and Australia were presented the MVP story. As a result of those meetings there was strong demand for shares and for more liquidity from a number of financial institutions through Jefferies Securities of Hong Kong and Bell Potter in Australia.

Mr. Williams said: "I remain MVP's biggest shareholder and own 8,671,045 shares (14.67% of MVP stock). As Chairman I am delighted and proud of the progress MVP is making and I view the strong demand from financial institutions as a vote of confidence in the future of MVP." Mr. Williams said "We are quickly building a global business and a global shareholder base. I am told the shares sold yesterday went to funds in Australia, US and UK."

Enquiries:

John Sharman

Chief Executive Officer

Medical Developments International Ltd

03 9547 1888

David Williams

Chairman

Medical Developments International Ltd

0414 383 593

**About Pentrox**

Penthrox is a non-opioid, non-addictive, inhaled analgesic indicated in Australia for pain relief by self-administration in patients with trauma and those requiring analgesia for surgical procedures. Penthrox has been used for more than 40 years in Australia and is now sold into 16 countries with circa 6.0 million units sold. There is growing interest in Penthrox being used in patients undergoing investigatory procedures, as well as operational procedures such as colonoscopy.

About Medical Developments International Ltd

MVP is an Australian company delivering emergency medical solutions dedicated to improving patient outcomes. MVP is a leader in emergency pain relief and respiratory products. The Company manufactures Penthrox®, an analgesic product. It is used in Australian Hospitals including Emergency Departments, Australian Ambulance Services, the Australian Defense Forces, Sports Medicine and for analgesia during short surgical procedures such as Dental and Cosmetic surgery. MVP is expanding internationally and manufactures a range of world-leading Asthma respiratory devices.